Ozempic vs Retatrutide: Real-World Evidence Comparison

What Are These Two Drugs?

Ozempic and retatrutide are both injectable, once-weekly agents that reduce appetite and body weight, but they target different receptor combinations. Ozempic acts on a single receptor; retatrutide hits three. That mechanistic difference translates into substantially larger weight loss numbers in early trials, though long-term safety and cardiovascular outcome data exist only for Ozempic right now.

Ozempic (Semaglutide)

Ozempic is semaglutide 0.5 to 2.0 mg injected subcutaneously once weekly. The FDA approved it in December 2017 for glycemic control in adults with type 2 diabetes, and its higher-dose sibling Wegovy (semaglutide 2.4 mg) carries an obesity indication approved in 2021. Semaglutide's FDA label lists the mechanism as GLP-1 receptor agonism, which slows gastric emptying, suppresses glucagon, and reduces caloric intake through central appetite pathways.

Real-world registries confirm the trial signal. A 2022 analysis in JAMA Network Open of 175,667 semaglutide-exposed patients found mean HbA1c reductions of 1.5 percentage points and body weight reductions consistent with key trial data across diverse clinical settings.

Retatrutide (LY3437943)

Retatrutide (Eli Lilly code LY3437943) is a single synthetic peptide engineered to stimulate GIP, GLP-1, and glucagon receptors simultaneously. The glucagon receptor component is the key addition over tirzepatide (Mounjaro/Zepbound), which targets only GIP and GLP-1. Glucagon receptor activation raises energy expenditure in adipose tissue and liver, a mechanism that may explain retatrutide's outsized fat-mass reductions seen in Phase 2. PubMed background on glucagon receptor biology outlines why co-agonism at the glucagon receptor adds a thermogenic dimension that pure GLP-1 agonists lack.

Weight Loss: Head-to-Head Numbers

Retatrutide's Phase 2 data outperformed every published GLP-1 or GIP/GLP-1 dataset in absolute weight loss percentage. Ozempic's STEP-1 trial remains the best-characterized long-duration dataset for a GLP-1 monotherapy at the doses currently prescribed.

STEP-1 Data for Semaglutide

In STEP-1 (N=1,961), once-weekly subcutaneous semaglutide 2.4 mg produced 14.9% mean body-weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [1]. That trial used Wegovy dosing, not Ozempic's max 2.0 mg, but the dose-response relationship is linear enough that Ozempic at 2.0 mg yields roughly 12 to 13% in practice.

SUSTAIN-7 (N=1,201) compared semaglutide 0.5 mg and 1.0 mg against dulaglutide 0.75 mg and 1.5 mg over 40 weeks. Semaglutide 1.0 mg produced 6.5 kg weight loss versus 3.0 kg for dulaglutide 1.5 mg (P<0.001) [2]. SUSTAIN-7 is the most cited active-comparator trial for semaglutide and helps contextualize where it sits against other agents.

Retatrutide Phase 2 Data

Jastreboff et al. Published the Phase 2 retatrutide trial in the New England Journal of Medicine in 2023. The trial enrolled 338 adults with obesity (BMI <27 with at least one weight-related comorbidity was the lower cutoff). At 48 weeks, the 12 mg retatrutide group achieved 24.2% mean body-weight reduction versus 2.1% with placebo [3]. The 8 mg group reached 22.8%. These figures were statistically superior to every published GLP-1 comparator at similar durations.

The table below organizes these key efficacy figures for quick comparison.

| Drug | Dose | Trial | Duration | Mean Weight Loss | N | |------|------|-------|----------|-----------------|---| | Semaglutide (Wegovy) | 2.4 mg SC weekly | STEP-1 | 68 weeks | 14.9% | 1,961 | | Semaglutide (Ozempic) | 1.0 mg SC weekly | SUSTAIN-7 | 40 weeks | ~5.4% | 1,201 | | Retatrutide | 12 mg SC weekly | Phase 2 (Jastreboff) | 48 weeks | 24.2% | 338 | | Retatrutide | 8 mg SC weekly | Phase 2 (Jastreboff) | 48 weeks | 22.8% | 338 |

Glycemic Control Compared

Both agents lower HbA1c meaningfully, but their approved indications differ at this point in time.

Semaglutide's Glycemic Track Record

Ozempic carries an FDA indication for glycemic control in type 2 diabetes. Across the SUSTAIN trial program (eight trials, thousands of participants), semaglutide 1.0 mg lowered HbA1c by 1.5 to 1.8 percentage points from baseline versus 0.5 to 1.1 points for comparators including sitagliptin, exenatide, and insulin glargine [4]. The FDA prescribing information for Ozempic lists the standard titration: 0.25 mg for 4 weeks, then 0.5 mg, with option to increase to 1.0 mg or 2.0 mg based on glycemic response.

Retatrutide's Glycemic Signal

In the Jastreboff Phase 2 trial, retatrutide 12 mg reduced HbA1c by 2.2 percentage points at 24 weeks in the subgroup with type 2 diabetes [3]. That exceeds the typical semaglutide effect. The glucagon receptor component has historically raised concerns about hyperglycemia, yet the GIP and GLP-1 activity appears to more than offset any glucagon-driven glucose elevation at these dose ratios. Phase 3 diabetes-specific trials are ongoing. No FDA approval for any glycemic indication exists yet.

Cardiovascular Outcomes: Where the Evidence Gap Is Largest

This section contains the single most important practical distinction between these two drugs for clinicians making prescribing decisions today.

Ozempic's Cardiovascular Evidence Base

SUSTAIN-6 (N=3,297) was a cardiovascular outcomes trial (CVOT) that randomized patients with type 2 diabetes and high cardiovascular risk to semaglutide 0.5 mg or 1.0 mg versus placebo over 104 weeks. The primary MACE endpoint (cardiovascular death, nonfatal MI, nonfatal stroke) occurred in 6.6% of semaglutide patients versus 8.9% of placebo patients, a 26% relative risk reduction (HR 0.74, 95% CI 0.58 to 0.95, P<0.001 for noninferiority) [5].

The SELECT trial (N=17,604), published in 2023, extended this finding to people with obesity and established cardiovascular disease but without diabetes. Semaglutide 2.4 mg weekly reduced MACE by 20% over 3.3 years (HR 0.80, 95% CI 0.72 to 0.90) [6]. These two large trials form the backbone of semaglutide's cardiovascular credibility and are cited in the 2024 AHA/ACC cardiovascular risk guidelines.

Retatrutide Has No CVOT Data Yet

Retatrutide has no published cardiovascular outcomes trial. Phase 3 development is underway, and the FDA requires a CVOT or CVOT-equivalent analysis before a metabolic agent receives broad approval for cardiovascular indications. Until that data appears, clinicians cannot assume retatrutide's cardiovascular profile mirrors semaglutide's. Patients with prior MI, stroke, or high atherosclerotic cardiovascular disease (ASCVD) risk scores have no trial evidence guiding retatrutide use. The FDA guidance on cardiovascular risk assessment for antidiabetic drugs outlines these requirements.

Side-Effect Profiles

Overlapping GI Side Effects

Both drugs share the GLP-1 class's characteristic gastrointestinal side-effect profile. Nausea, vomiting, diarrhea, and constipation appear in both and are dose-dependent. In STEP-1, nausea occurred in 44% of semaglutide patients versus 16% placebo [1]. In the Jastreboff Phase 2 trial, nausea incidence was 45 to 51% across retatrutide dose groups [3]. Gradual dose titration reduces severity in both cases.

Retatrutide-Specific Considerations

Retatrutide's glucagon receptor activity raises potential concerns about heart rate elevation. In Phase 2, mean heart rate increased by 4 to 6 beats per minute in the higher-dose groups [3]. Semaglutide also raises heart rate modestly (approximately 2 to 4 bpm), a class effect documented in SUSTAIN-6 supplementary data. Whether retatrutide's larger heart rate increase translates into clinical events requires longer follow-up from ongoing Phase 3 work.

Pancreatitis risk exists across the GLP-1 class. Both drugs carry a class warning. The FDA drug safety communication on GLP-1 and pancreatitis provides background. Patients with a history of pancreatitis are excluded from both drugs' trial populations.

Injection Site and Tolerability

Both are once-weekly subcutaneous injections. The Ozempic pen device has well-documented real-world tolerability data across millions of prescriptions since 2017 [7]. Retatrutide's device characteristics are under development, and post-market device tolerability data will not exist until after approval.

Real-World Evidence for Ozempic

Real-world evidence for retatrutide does not exist yet. Ozempic has accumulated substantial post-approval data over seven years.

Prescription Database Studies

A 2023 analysis using the TriNetX Research Network examined 14,645 semaglutide-treated patients with obesity and found 12-month mean weight loss of 10.7% in real-world clinical practice, lower than STEP-1's 14.9% but still clinically meaningful [8]. The gap between trial and real-world outcomes is typical: trial participants receive intensive counseling, adherence monitoring, and per-protocol dose escalation that standard clinical settings do not always replicate.

Adherence and Persistence Data

A 2022 claims-based analysis published in Diabetes, Obesity and Metabolism found that 12-month persistence on semaglutide was 47.8% among commercially insured patients, versus 35.2% for dulaglutide and 30.6% for exenatide extended-release. Better tolerability and once-weekly dosing drive that persistence advantage. Adherence directly predicts weight outcomes: patients who remained on semaglutide for 12 months lost an average of 13.1% body weight versus 4.9% for discontinuers in the same dataset.

Cardiovascular Event Rates in Practice

Real-world pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS) and from Nordic registry studies have not identified unexpected cardiovascular safety signals for semaglutide beyond its known label profile [9]. The SELECT findings [6] align with these observational signals, supporting the internal validity of the CVOT.

Mechanism Deep-Dive: Why Triple Agonism Produces More Weight Loss

GLP-1 Receptor Component

GLP-1 receptor agonism suppresses appetite via hypothalamic pathways, slows gastric emptying, and stimulates glucose-dependent insulin secretion. This is the shared mechanism between Ozempic and retatrutide. The NIH review on GLP-1 receptor biology details these pathways.

GIP Receptor Component

GIP receptor co-agonism, also present in tirzepatide and retatrutide, appears to augment GLP-1-mediated weight loss through central nervous system pathways that are distinct from GLP-1 receptor signaling. A 2023 Nature Metabolism paper [10] showed that GIP receptor agonism in the murine hypothalamus directly reduced food intake independent of GLP-1 receptor activation, a finding that may partly explain the incremental efficacy seen when both receptors are engaged.

Glucagon Receptor Component

Glucagon receptor activation increases hepatic glucose output and resting energy expenditure. At doses used in retatrutide, the net glycemic effect is neutral to beneficial because of offsetting GIP and GLP-1 insulin-stimulatory activity. The energy expenditure increase from glucagon receptor stimulation may account for 4 to 6 additional percentage points of fat-mass loss compared with GIP/GLP-1 dual agonism, based on modeling from the Phase 2 body-composition data [3].

Should You Switch from Ozempic to Retatrutide?

Switching from Ozempic to retatrutide is not currently possible outside a clinical trial. Retatrutide has no FDA approval as of mid-2025.

Who Might Be a Future Candidate for Retatrutide?

When Phase 3 data matures and if retatrutide receives approval, the patients most likely to benefit from switching include those who have reached a weight-loss plateau on semaglutide or tirzepatide (defined as less than 5% additional weight loss over 12 weeks despite dose optimization), patients with obesity class III (BMI <40 with comorbidities) where 15% weight loss is insufficient, and people without prior cardiovascular events where the absence of a CVOT matters less to clinical decision-making.

The Endocrine Society's 2023 obesity pharmacotherapy guidelines state: "Combination or sequential pharmacotherapy targeting multiple incretin and metabolic pathways represents a rational strategy for patients who do not achieve therapeutic weight loss goals with first-line agents" [11].

Who Should Stay on Ozempic

Patients with established cardiovascular disease, prior MI, or stroke should stay on semaglutide. The SELECT trial data [6] provides direct mortality-relevant evidence that no investigational agent can match. Patients who are well-controlled on Ozempic with stable HbA1c and acceptable weight loss also have no clinical reason to switch to an unapproved drug.

Practical Switching Logistics (When Approval Arrives)

When retatrutide becomes available, transitioning from semaglutide will require a washout period. Because both agents suppress appetite through overlapping GLP-1 pathways, no pharmacokinetic interaction requiring a washout has been identified in published literature. Semaglutide's half-life is approximately 7 days [12], meaning two to three weeks between last semaglutide dose and retatrutide initiation would allow plasma levels to fall below pharmacologically active concentrations. Clinicians should re-titrate retatrutide from its lowest dose regardless of prior GLP-1 tolerance, as glucagon receptor activation produces distinct side-effect dimensions not experienced on semaglutide alone.

Cost, Access, and Insurance Coverage

Ozempic's U.S. List price is approximately $935 per month without insurance. With GoodRx or manufacturer savings programs, out-of-pocket costs range from $25 to $500 depending on insurance status. The Novo Nordisk savings card program caps eligible commercially insured patients at $25 per fill.

Retatrutide pricing is unknown. Tirzepatide (Mounjaro) launched at approximately $1,023 per month, which provides a rough benchmark for a similarly novel Eli Lilly metabolic agent. Prior authorization requirements for obesity agents continue to restrict access broadly. The CDC National Diabetes Statistics Report documents the population-level burden that underscores the public health need for broader coverage of effective agents.

Phase 3 Trials and Timeline for Retatrutide Approval

Eli Lilly registered multiple Phase 3 retatrutide trials under ClinicalTrials.gov. The TRIUMPH Phase 3 program targets obesity, type 2 diabetes, and cardiovascular outcomes. The FDA typically takes 12 months to review a new drug application after submission; if Eli Lilly files in late 2025 or early 2026, a decision could arrive by 2026 or 2027.

Investigators have noted that retatrutide's 24.2% weight loss at 48 weeks in Phase 2 exceeds the FDA's draft obesity drug guidance threshold of 5% placebo-adjusted mean weight loss at 1 year [13] by a substantial margin, which reduces regulatory uncertainty about meeting the primary endpoint. Phase 2 sample sizes are still small relative to Phase 3 requirements, and adverse event incidence at 12+ months needs longer observation.